Table 1 Clinicopathological characteristics of robot-assisted radical prostatectomy.
Median (IQR) or n (%) | |
|---|---|
Number of patients | 254 |
Age, years | 67 (64–71) |
Body mass index | 23.6 (21.9–25.6) |
Prostate specific antigen, ng/ml | 6.6 (5.0–9.2) |
Biopsy Gleason Grade Group | |
1 | 54 (21%) |
2 | 72 (29%) |
3 | 57 (22%) |
4 | 61 (24%) |
5 | 10 (4%) |
Clinical stage | |
≦ T2 | 247 (97%) |
T3 ≦ | 7 (3%) |
D'Amico risk classification | |
Low | 48 (19%) |
Intermediate | 112 (44%) |
High | 94 (37%) |
NADT | |
No | 235 (93%) |
Yes | 19 (7%) |
IPSS total score | 9 (6–14) |
ICIQ-UI SF total score | 0 (0–2) |
Nerve-sparing | |
Non | 45 (18%) |
Unilateral | 175 (69%) |
Bilateral | 34 (13%) |
Surgical time, min | 253 (212–278) |
Console time, min | 177 (151–214) |
PLND | |
Non | 184 (72%) |
Limited | 47 (19%) |
Exteded | 23 (9%) |
Retzius-sparing, Yes | 58 (23%) |
Bleeding, mL | 100 (30–150) |
Blood transfusion, Yes | 0 (0%) |
Clavien-Dindo classification | |
Grade 2 or less | 254 (100%) |
Grade 3 or grater | 0 (0%) |
Removed prostate volume, gr | 39.5(31.0–49.0) |
Catheter indwelling duration, days | 7 (7–7) |
Positive surgical margin | 54 (21%) |
Extraprostatic extension | 39 (15%) |
Urine loss ratio, % | 4.0 (0.5–19.6) |
Membranous urethral length, mm | 11 (9–12) |
UVJ movement, mm | 1 (0–3) |
PB-AR change, mm | 1 (0–3) |
